Glycoengineered CD20 antibodies induce PMN cell death. CLL cells were labeled with PKH26 and incubated in whole blood from a healthy donor in the presence or absence of 10 µg/mL of nonglycoengineered wild-type (WT) or glycoengineered (GE) CD20 antibodies, control TRZ, or 0.1 µM of PMA (panel A). In some experiments, 10 µg/mL of anti-CD16 or anti-CD32 F(ab’)₂ fragments were added alone or in combination with each other or with glycoengineered rituximab (panel B). PMN cell death was measured by flow cytometry (7-AAD⁺/CD15⁺) after 24-hour incubation. The results are the mean and standard deviations of 4 to 8 experiments. In both panels, the statistical significance is analyzed for antibody-treated samples with respect to untreated control.